Next 10 |
2024-03-28 09:06:17 ET “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024. Vertex Pharmaceuticals Inc (NASDAQ: VRTX) ...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults PR Newswire SAN DIEGO , March 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), tod...
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March PR Newswire UBS Virtual CNS Day 2024 Conference on March 18 Stifel 2024 Virtual CNS Days Conference on March 19 SAN DIEGO , March 11, 2024 /PRNewswire/ -- Neuro...
2024-02-24 08:00:00 ET Summary Vanguard S&P Mid-Cap 400 Growth Index Fund ETF Shares uses sales growth, earnings growth, and momentum to select stocks in the S&P Mid-Cap 400 Index. The VOG ETF overweights industrials and underweights financials compared to the parent index...
2024-02-16 13:50:39 ET More on Electronic Arts, Dave & Buster's, etc. Dave & Buster's: New Management, Promising Future Mayar Capital - Electronic Arts: Favorable Trends Coming Through In The Financials Electronic Arts: Strong Cash Flows And Buybacks Ma...
2024-02-11 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-10 20:30:24 ET Summary Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted spending to grow the Ingrezza business (Huntingto...
2024-02-08 16:30:05 ET Summary Today, we focused on Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics for neurological disorders. The company has experienced "setbacks" in recent trials, but its primary drug candidate, XEN110...
2024-02-07 12:58:06 ET Neurocrine Biosciences Inc. (NBIX) Q4 2023 Earnings Conference Call February 7, 2024 8:00 am ET Company Participants Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer ...
2024-02-07 07:01:21 ET More on Neurocrine Biosciences Neurocrine Biosciences: Fear Not The IRA Neurocrine Biosciences Q4 2023 Earnings Preview Bristol-Karuna deal: What other biotechs might be in M&A crosshairs? Seeking Alpha’s Quant Rating on Neur...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
2024-03-28 09:06:17 ET “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024. Vertex Pharmaceuticals Inc (NASDAQ: VRTX) ...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults PR Newswire SAN DIEGO , March 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), tod...
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differenti...